Podcast series: What’s new in mCRPC?
In this section
Episode 1: Can progress in mCRPC improve daily clinical practice?
It's great, not only that we have a new treatment, but perhaps even more important that we have a new target, which is prostate-specific membrane antigen (PSMA).
Professor Karim Fizazi and Dr Elena Castro discuss the clinical impact of the latest developments in metastatic castration-resistant prostate cancer (mCRPC) and patients’ perceptions.
Episode 2: Guidelines are for people not diseases: Improving implementation
Guidelines can actually tell us what we should do when data are available, and the level of evidence is actually provided in guidelines, but often there is no evidence.
Professor Karim Fizazi and Dr Elena Castro discuss the available guidelines for the treatment of metastatic castration-resistant prostate cancer (mCRPC), their limitations and what to do when drug approvals outpace the guidelines.
Episode 3: Changing treatment approaches for mCRPC: What’s the evidence?
There are many patients who do not receive chemo or who just don’t want to receive chemo. So it’s important to develop drugs for these patients.
Professor Karim Fizazi and Professor Silke Gillessen discuss the evidence for optimal use of both older and more recent treatments for mCRPC, and the role of next-generation sequencing.
Episode 4: Looking ahead: Treatment questions and emerging targets in mCRPC
We have to be smart to select the correct patients for immunotherapy in general.
Professors Karim Fizazi and Silke Gillessen discuss ongoing research in mCRPC, in-development treatments including immunotherapies, and emerging treatment targets.
of interest
are looking at
saved
next event
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, who has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.